Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1 , were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5′ untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1 . Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high expression levels of ERG and PEA3 subfamily members in a subset of prostate tumors led to the discovery of common chromosomal rearrangements associated with this human cancer (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Chromosomal rearrangements that result in the overexpression of members of the PEA3 subfamily (ETV1, ETV4, or ETV5) are found less frequently (36, 170, 171).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Rearrangements of ETS loci are a hallmark of prostate cancer with ~50% of tumors showing alterations at an ETS gene locus (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationChromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Research works printed but not linked: 5
- I. S. Jeon et al., Oncogene10, 1229 (1995).
- B. Lin et al., Cancer Res.59, 4180 (1999).
- D. E. Afar et al., Cancer Res.61, 1686 (2001).
- S. M. Dhanasekaran et al., FASEB J.19, 243 (2005).
- J. B. Welsh et al., Cancer Res.61, 5974 (2001).
Cited by
Items 701–800 of 1,014
Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
Imamura, Y., & Sadar, M. D. (2016) · International Journal of Urology · doi:10.1111/iju.13137 · Cited by 86
Promotion and maintenance of leukemia by ERG
Tsuzuki, S., Taguchi, O., & Seto, M. (2011) · Blood · doi:10.1182/blood-2010-11-320515 · Cited by 95
Urinary biomarkers for prostate cancer: a review
Hessels, D., & Schalken, J. A. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.6 · Cited by 98
MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression
Dallavalle, C., Albino, D., Civenni, G., Merulla, J., Ostano, P., Grand, M. M., Rossi, S., Losa, M., D’Ambrosio, G., Sessa, F., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86505 · Cited by 89
Diagnostic and prognostic molecular biomarkers for prostate cancer
Kristiansen, G. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04083.x · Cited by 97
Chen, J., Zhang, D., Yan, W., Yang, D., & Shen, B. (2013) · BioMed Research International · doi:10.1155/2013/901578 · Cited by 100
ETS transcription factors as emerging drug targets in cancer
Hsing, M., Wang, Y. Z., Rennie, P. S., Cox, M., & Cherkasov, A. R. (2019) · Medicinal Research Reviews · doi:10.1002/med.21575 · Cited by 100
Urine markers in monitoring for prostate cancer
Jamaspishvili, T., Král, M., Khomeriki, I., Študent, V., Kolář, Z., & Bouchal, J. (2009) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2009.31 · Cited by 96
Shin, S., Kim, T.-D., Jin, F., van Deursen, J. M., Dehm, S. M., Tindall, D. J., Grande, J. P., Munz, J.-M., Vasmatzis, G., & Janknecht, R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0941 · Cited by 85
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
Nannini, M., Astolfi, A., Urbini, M., Indio, V., Santini, D., Heinrich, M. C., Corless, C. L., Ceccarelli, C., Saponara, M., Mandrioli, A., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-685 · Cited by 87
An, Q., Wright, S. L., Konn, Z. J., Matheson, E. C., Minto, L., Moorman, A. V., Parker, H., Griffiths, M., Ross, F. M., Davies, T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803494105 · Cited by 87
Tumor focality in prostate cancer: implications for focal therapy
Karavitakis, M., Ahmed, H. U., Abel, P. D., Hazell, S., & Winkler, M. H. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.190 · Cited by 87
Berg, K. D., Vainer, B., Thomsen, F. B., Røder, M. A., Gerds, T. A., Toft, B. G., Brasso, K., & Iversen, P. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.058 · Cited by 92
“The gene fusion between TMPRSS2 and ERG, primarily a consequence of chromosomal rearrangement or interstitial deletion, was identified as a common genetic alteration in PCa occurring in 40–70% of tumours [4].”
BackgroundSchoenborn, J. R., Nelson, P., & Fang, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3606 · Cited by 98
EndoDB: a database of endothelial cell transcriptomics data
Khan, S., Taverna, F., Rohlenová, K., Treps, L., Geldhof, V., de Rooij, L. P. M. H., Sokol, L., Pircher, A., Conradi, L., Kalucka, J. M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky997 · Cited by 91
Illuminating the noncoding genome in cancer
Zhang, X., & Meyerson, M. M. (2020) · Nature Cancer · doi:10.1038/s43018-020-00114-3 · Cited by 87
Shah, N., Lankerovich, M., Lee, H., Yoon, J.-G., Schroeder, B., & Foltz, G. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-818 · Cited by 84
Reanalysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms
Kangaspeska, S., Hultsch, S., Edgren, H., Nicorici, D., Murumägi, A., & Kallioniemi, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048745 · Cited by 100
Yamaoka, M., Hara, T., & Kusaka, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0255 · Cited by 94
Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers
Kontos, C. K., & Scorilas, A. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0247 · Cited by 92
Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Hu, N., Kadota, M., Liu, H., Abnet, C. C., Su, H., Wu, H., Freedman, N. D., Yang, H. H., Wang, C., Yan, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0338 · Cited by 102
Tosoian, J. J., Almutairi, F., Morais, C. L., Glavaris, S. A., Hicks, J. L., Sundi, D., Humphreys, E. B., Han, M., Marzo, A. M. D., Ross, A. E., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.07.026 · Cited by 89
Self-citationTranscriptional consequences of genomic structural aberrations in breast cancer
Inaki, K., Hillmer, A. M., Ukil, L., Yao, F., Woo, X. Y., Vardy, L. A., Zawack, K. F. B., Lee, C. W. H., Ariyaratne, P. N., Chan, Y. S., et al. (2011) · Genome Research · doi:10.1101/gr.113225.110 · Cited by 90
“Similar to the multiple fusion patterns in TMPRESS-ETS gene family fusions in prostate cancer (Tomlins et al. 2005), we also found multiple fusion points in the abnormal transcripts by RT-PCR and sequencing (total 10 fusion types) (Fig.”
BackgroundSelf-citationSex hormones and prostate cancer
Auchus, R. J., & Sharifi, N. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051418-060357 · Cited by 85
Molecular pathology and its diagnostic use in bone tumors
Szuhai, K., Cleton-Jansen, A., Hogendoorn, P. C. W., & Bovée, J. V. M. G. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.04.001 · Cited by 93
Prevalence and clinical implications of chromothripsis in cancer genomes
Kloosterman, W. P., Köster, J., & Molenaar, J. J. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000038 · Cited by 91
Rayford, W., Beksac, A. T., Alger, J., Alshalalfa, M., Ahmed, M., Khan, I., Falagario, U. G., Liu, Y., Davicioni, E., Spratt, D. E., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02140-y · Cited by 89
Rohan, J. P., & Weigel, N. L. (2009) · Endocrinology · doi:10.1210/en.2008-1395 · Cited by 86
Cullin 3 Ubiquitin Ligases in Cancer Biology: Functions and Therapeutic Implications
Chen, H., & Chen, R. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00113 · Cited by 94
MASTER REGULATORS USED AS BREAST CANCER METASTASIS CLASSIFIER
Lim, W. K., Lyashenko, E., & Califano, A. (2008) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789812836939_0048 · Cited by 87
Molecular biology of prostate-cancer pathogenesis
Shand, R. L., & Gelmann, E. P. (2006) · Current Opinion in Urology · doi:10.1097/01.mou.0000193384.39351.64 · Cited by 84
Albertelli, M. A., Scheller, A., Brogley, M. A., & Robins, D. M. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0021 · Cited by 86
Targeting chromatin complexes in fusion protein-driven malignancies
Brien, G. L., Stegmaier, K., & Armstrong, S. A. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0132-x · Cited by 86
Li, Y., Yang, R., Henzler, C. M., Ho, Y., Passow, C. N., Auch, B., Carreira, S., Rodrigues, D. N., Bertan, C. M., Hwang, T. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3023 · Cited by 92
Transcriptional network of androgen receptor in prostate cancer progression
Takayama, K., & Inoue, S. (2013) · International Journal of Urology · doi:10.1111/iju.12146 · Cited by 90
Paulo, P., Ribeiro, F. R., Santos, J., Mesquita, D., Almeida, M. R., Barros-Silva, J. D., Itkonen, H. M., Henrique, R., Jerónimo, C., Sveen, A., et al. (2012) · Neoplasia · doi:10.1593/neo.12600 · Cited by 91
CYP17A1 inhibitors in castration-resistant prostate cancer
Gomez, L., Kovac, J. R., & Lamb, D. J. (2015) · Steroids · doi:10.1016/j.steroids.2014.12.021 · Cited by 91
Global Genomic Characterization of Acute Lymphoblastic Leukemia
Mullighan, C. G., & Downing, J. R. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.005 · Cited by 93
Mrózek, K., Döhner, H., & Bloomfield, C. D. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32801684c7 · Cited by 84
Cheville, J. C., Karnes, R. J., Therneau, T. M., Kosari, F., Munz, J.-M., Tillmans, L. S., Basal, E., Rangel, L. J., Bergstralh, E. J., Kovtun, I. V., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6752 · Cited by 84
Nowak, D. G., Cho, H., Herzka, T., Watrud, K., DeMarco, D. V., Wang, V. M. Y., Senturk, S., Fellmann, C., Ding, D., Beinortas, T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1113 · Cited by 79
Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy
Kgatle, M. M., Kalla, A. A., Islam, M. M., Sathekge, M. M., & Moorad, R. (2016) · Prostate Cancer · doi:10.1155/2016/5653862 · Cited by 96
Approaches to urinary detection of prostate cancer
Eskra, J. N., Rabizadeh, D., Pavlovich, C. P., Catàlona, W. J., & Luo, J. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0127-4 · Cited by 88
Single-cell mRNA cytometry via sequence-specific nanoparticle clustering and trapping
Labib, M., Mohamadi, R. M., Poudineh, M., Ahmed, S. U., Ivanov, I., Huang, C.-L., Moosavi, M., Sargent, E. H., & Kelley, S. O. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0025-8 · Cited by 88
The impact of SARS-CoV-2 and COVID-19 on male reproduction and men’s health
Patel, D. P., Punjani, N., Guo, J., Alukal, J. P., Li, P. S., & Hotaling, J. M. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.12.033 · Cited by 87
“Gene fusions of TMPRSS2with ETS/ERG transcription factors have been associated with prostate cancer in an androgen-sensitive manner (66).”
Wnt11 in 2011 – the regulation and function of a non‐canonical Wnt
Onganer, P. U., & Kypta, R. M. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02297.x · Cited by 83
Direct Electrocatalytic mRNA Detection Using PNA-Nanowire Sensors
Fang, Z., & Kelley, S. O. (2008) · Analytical Chemistry · doi:10.1021/ac801890f · Cited by 83
Molecular markers of prostate cancer
Bradford, T. J., Tomlins, S. A., Wang, X., & Chinnaiyan, A. M. (2006) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2006.07.004 · Cited by 90
Self-citationDiffner, E., Beck, D., Gudgin, E. J., Thoms, J. A. I., Knezevic, K., Pridans, C., Foster, S., Goode, D. K., Lim, W. K., Boelen, L., et al. (2013) · Blood · doi:10.1182/blood-2012-07-446120 · Cited by 83
Cells of origin for cancer: an updated view from prostate cancer
Xin, L. (2013) · Oncogene · doi:10.1038/onc.2012.541 · Cited by 73
Ishkanian, A., Mallof, C. A., Ho, J., Meng, A. X., Albert, M., Syed, A., van der Kwast, T., Milosevic, M., Yoshimoto, M., Squire, J. A., et al. (2009) · The Prostate · doi:10.1002/pros.20959 · Cited by 83
Selvaraj, N., Kedage, V., & Hollenhorst, P. C. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0089-7 · Cited by 89
Androgen receptor corepressors and prostate cancer
Burd, C. J., Morey, L. M., & Knudsen, K. E. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01115 · Cited by 98
Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients
Mehra, R., Kumar‐Sinha, C., Shankar, S., Lonigro, R. J., Jing, X., Philips, N. E., Siddiqui, J., Han, B., Cao, X., Smith, D. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3120 · Cited by 83
Self-citationChen, R., Zeng, X., Zhang, R., Huang, J., Kuang, X., Yang, J., Liu, J., Tawfik, O. W., Thrasher, J. B., & Li, B. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.05.011 · Cited by 86
Activation of NF-κB by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4
Wang, J., Cai, Y., Shao, L., Siddiqui, J., Palanisamy, N., Li, R., Ren, C., Ayala, G., & Ittmann, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2210 · Cited by 82
Frequent down-regulation of ABC transporter genes in prostate cancer
Demidenko, R., Razanauskas, D., Daniūnaitė, K., Lazutka, J. R., Jankevičius, F., & Jarmalaitė, S. (2015) · BMC Cancer · doi:10.1186/s12885-015-1689-8 · Cited by 82
Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer
Magnen, C. L., Bubendorf, L., Rentsch, C. A., Mengus, C., Gsponer, J. R., Zellweger, T., Rieken, M., Thalmann, G. N., Cecchini, M. G., Germann, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2857 · Cited by 86
Targeting monoamine oxidase A in advanced prostate cancer
Flamand, V., Zhao, H., & Peehl, D. M. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0835-6 · Cited by 82
Metzger, E., Willmann, D., McMillan, J., Forné, I., Metzger, P., Gerhardt, S., Petroll, K., von Maessenhausen, A., Urban, S., Schott, A.-K., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3153 · Cited by 88
Self-citationERG gene rearrangement status in prostate cancer detected by immunohistochemistry
Falzarano, S. M., Zhou, M., Carver, P. D., Tsuzuki, T., Simmerman, K., He, H., & Magi‐Galluzzi, C. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1128-4 · Cited by 81
Perner, S., Wagner, P., Soltermann, A., Lafargue, C. J., Tischler, V., Weir, B. A., Weder, W., Meyerson, M. M., Giordano, T. J., Moch, H., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2443 · Cited by 81
Self-citationYoshimoto, M., Ding, K., Sweet, J., Ludkovski, O., Trottier, G., Song, K. S., Joshua, A. M., Fleshner, N. E., Squire, J. A., & Evans, A. J. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.162 · Cited by 81
Wang, S., Chen, Y., Wang, Y.-C., Wang, W., Yang, C., Tsai, C.-L., Hou, M., Chen, H., Shen, Y.-C., & Hung, M. (2020) · PubMed · Cited by 81
Endothelial ERG alleviates cardiac fibrosis via blocking endothelin-1-dependent paracrine mechanism
Zhang, X., Hu, C., Yuan, Y., Song, P. K., Kong, C., Wu, H., Xu, S., Ma, Z., & Tang, Q. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09581-5 · Cited by 84
An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer
Wang, X. S., Prensner, J. R., Chen, G., Cao, Q., Han, B., Dhanasekaran, S. M., Ponnala, R., Cao, X., Varambally, S., Thomas, D. G., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1584 · Cited by 102
Self-citationBraun, M., Goltz, D., Adler, D., Vogel, W., Böhm, D., Scheble, V. J., Sotlar, K., Fend, F., Tan, S., Dobi, A., et al. (2012) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.67 · Cited by 81
Self-citationCarden, C. P., Sarker, D., Postel-Vinay, S. C., Yap, T. A., Attard, G., Banerji, U., Garrett, M. D., THOMAS, G. V., Workman, P., Kaye, S. B., et al. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.006 · Cited by 89
Novel Fusion Transcripts Associate with Progressive Prostate Cancer
Yu, Y. P., Ding, Y., Chen, Z., Liu, S., Michalopoulos, A., Chen, R., Gulzar, Z. G., Yang, B., Cieply, K. M., Luvison, A., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.06.025 · Cited by 90
Big data mining yields novel insights on cancer
Jiang, P., & Liu, X. S. (2015) · Nature Genetics · doi:10.1038/ng.3205 · Cited by 80
Lui, W., Zeng, L., Rehrmann, V., Deshpande, S. S., Tretiakova, M., Kaplan, E. L., Leibiger, I. B., Leibiger, B., Enberg, U., Höög, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1085 · Cited by 85
Petrovics, G., Li, H., Stümpel, T., Tan, S., Young, D., Katta, S., Li, Q., Ying, K., Klocke, B., Ravindranath, L., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.10.028 · Cited by 88
Strategies for plasma proteomic profiling of cancers
Omenn, G. S. (2006) · PROTEOMICS · doi:10.1002/pmic.200600331 · Cited by 85
Transcriptional Regulation in Prostate Cancer
Labbé, D. P., & Brown, M. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030437 · Cited by 83
“The TMPRSS2-ERG gene fusion (Tomlins et al. 2005), observed in 46% of primary prostate cancer, is by far the most frequent chromosomal rearrangement involving ETS family members, followed by ETV1 (8% [Tomlins et al. 2005]), ETV4 (4% [Tomlins et al. 2006]), andFLI1 (<1”
BackgroundPriemer, D. S., Montironi, R., Wang, L., Williamson, S. R., Antonio Lopez-beltran, B., & Liang Cheng, C. (2016) · Endocrine Pathology · doi:10.1007/s12022-016-9421-z · Cited by 79
Tan, S., Petrovics, G., & Srivastava, S. K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041255 · Cited by 83
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. T., & Preković, S. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0289 · Cited by 85
Phosphorylation regulates cullin-based ubiquitination in tumorigenesis
Chen, Y., Shao, X., Cao, J., Zhu, H., Yang, B., He, Q., & Ying, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.007 · Cited by 84
Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis
Matuszczak, M., Schalken, J. A., & Salagierski, M. (2021) · Cancers · doi:10.3390/cancers13133373 · Cited by 79
“Cancers 2021, 13, 3373 6 of 29 Cancers 2021, 13, 3373 7 of 29 PCA3 shows more significant diagnostic and prognostic potential when combined with other biomarkers, such as TMPRSS2 fusion: ERG [36] hK2, PSA [37] and PSAD [38].”
BackgroundInfluentialNewcomb, L. F., Brooks, J. D., Carroll, P. R., Feng, Z., Gleave, M. E., Nelson, P. S., Thompson, I. M., & Lin, D. W. (2009) · Urology · doi:10.1016/j.urology.2009.05.050 · Cited by 79
Schröder, F. H. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.049 · Cited by 92
“Since the original publication [25] at least 14 studies have appeared that confirm the presence of TMPRSS2-ETS family member fusions in a large proportion of clinical cases or prostate cancer lines [42–47].”
BackgroundFarrell, J. S., Petrovics, G., McLeod, D. G., & Srivastava, S. K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140815510 · Cited by 81
Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1007 · Cited by 76
Komiya, T., Park, Y., Modi, S., Coxon, A. B., Oh, H., & Kaye, F. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209627 · Cited by 79
“…has been recent interest in the unexpected detection of fusion oncogenes in epithelial solid tumors (Tognon et al., 2002; Mitelman et al., 2004; Tomlins et al., 2005), we wished to determine if this tumor could serve as a useful epithelial model system for testing novel approaches directed…”
BackgroundRamos‐Montoya, A., Lamb, A. D. G., Russell, R. R., Carroll, T., Jurmeister, S., Galeano-Dalmau, N., Massie, C. E., Boren, J., Bon, H., Theodorou, V., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303581 · Cited by 92
Integrative Microarray Analysis of Pathways Dysregulated in Metastatic Prostate Cancer
Setlur, S. R., Royce, T. E., Sboner, A., Mosquera, J.-M., Demichelis, F., Hofer, M. D., Mertz, K. D., Gerstein, M., & Rubin, M. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2173 · Cited by 79
Self-citationHOOK3-RET : a novel type of RET/PTC rearrangement in papillary thyroid carcinoma
Ciampi, R., Giordano, T. J., Wikenheiser‐Brokamp, K. A., Koenig, R. J., & Nikiforov, Y. E. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0039 · Cited by 79
“Previously, the analysis of gene expression profiles allowed identification of the fusion between the TMPRSS2 and either the ETV1 or the ERG genes in prostate cancer (Tomlins et al. 2005).”
Translational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 86
Self-citationTET2 binds the androgen receptor and loss is associated with prostate cancer
Nickerson, M. L., Das, S., Im, K. M., Turan, S., Berndt, S. I., Li, H., Lou, H., Brodie, S. A., Billaud, J.-N., Zhang, T., et al. (2016) · Oncogene · doi:10.1038/onc.2016.376 · Cited by 85
New Developments in the Medical Management of Prostate Cancer
Kohli, M., & Tindall, D. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0442 · Cited by 87
Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression
Graff, R. E., Pettersson, A., Lis, R. T., Ahearn, T. U., Markt, S. C., Wilson, K. M., Rider, J. R., Fiorentino, M., Finn, S. P., Kenfield, S. A., et al. (2016) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.118703 · Cited by 83
Tiwari, R., Manzar, N., Bhatia, V., Yadav, A., Nengroo, M. A., Datta, D. B., Carskadon, S. L., Gupta, N., Sigouros, M., Khani, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14184-0 · Cited by 81
Oncoapoptotic signaling and deregulated target genes in cancers: Special reference to oral cancer
Khan, Z., & Bisen, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.04.002 · Cited by 90
“ERG1) [118].”
Stabilizing Androgen Receptor in Mitosis Inhibits Prostate Cancer Proliferation
Griend, D. J. V., Litvinov, I. V., & Isaacs, J. T. (2007) · Cell Cycle · doi:10.4161/cc.6.6.4028 · Cited by 78
TMPRSS2-ERG and PTEN loss in prostate cancer
Squire, J. A. (2009) · Nature Genetics · doi:10.1038/ng0509-509 · Cited by 78
Inhibition of the Ras-Net (Elk-3) Pathway by a Novel Pyrazole that Affects Microtubules
Wasylyk, C., Zheng, H., Castell, C., Debüssche, L., Multon, M.-C., & Wasylyk, B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2674 · Cited by 82
Chen, S.-Y., Cai, C., Fisher, C. J., Zheng, Z., Omwancha, J., Hsieh, C.-L., & Shemshedini, L. (2006) · Oncogene · doi:10.1038/sj.onc.1209705 · Cited by 86
“Recently, this gene was reported to undergo translocation with two ETs oncogenes in prostate cancer (Tomlins et al., 2005).”
BackgroundChimerDB 2.0—a knowledgebase for fusion genes updated
Kim, P., Yoon, S., Kim, N., Lee, S., Ko, M., Lee, H., Kang, H., Kim, J., & Lee, S. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp982 · Cited by 80
PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression
Park, M. K., Yao, Y., Xia, W., Setijono, S. R., Kim, J. H., Vila, I. K., Chiu, H.-H., Wu, Y., González‐Billalabeitia, E., Lee, M. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08481-x · Cited by 82
Biomarkers for prostate cancer
Leman, E. S., & Getzenberg, R. H. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22227 · Cited by 78
Metadata
- Authors
- Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109–0602, USA.
- Corresponding author
- Chinnaiyan, Arul M.
- ORCID
- Venue
- Science
- Published
- 2005-10-28
- Volume
- 310
- Issue
- 5748
- Pages
- 644-648
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2121158863
- Cited by
- 3,846
- References
- 32
- Citations by year
- 2026: 77 · 2025: 99 · 2024: 82 · 2023: 108 · 2022: 137 · 2021: 163 · 2020: 187 · 2019: 172 · 2018: 178 · 2017: 218 · 2016: 209 · 2015: 244 · 2014: 271 · 2013: 309 · 2012: 279
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG021404, R01 AG 21404)
- National Cancer Institute (UO1 CA111275-01, P50-CA-69568, U01CA111275, R01CA097063, R01 CA97063, 5P30 CA 46592, P50CA069568, P30CA046592)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- TMPRSS2-ERG fusion, prostate cancer, ETS transcription factors, chromosomal rearrangements, gene fusion, molecular diagnosis
- MeSH terms
- Transcriptional Regulator ERG, Androgens, DNA-Binding Proteins, Humans, Male, Membrane Proteins, Molecular Sequence Data, Neoplasm Proteins, Prostatic Neoplasms, Serine Endopeptidases, Transcription Factors, Translocation, Genetic, Gene Rearrangement, Oncogene Proteins, Fusion, Trans-Activators, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.